Levitra (Vardenafil)

Levitra belongs to the phosphodiesterase type 5 inhibitor class and is indicated for conditions affecting erectile function.

• Erectile dysfunction: improves the ability to achieve and maintain an erection sufficient for sexual activity when sexually stimulated.

• Vardenafil selectively inhibits the enzyme phosphodiesterase type 5 (PDE5) in the corpus cavernosum. By blocking PDE5, it prevents the breakdown of cyclic guanosine monophosphate (cGMP), leading to smooth‑muscle relaxation, increased blood flow to the penis, and facilitation of an erection in response to sexual stimulation.

Levitra may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Flushing: warmth and redness of the face or upper body.
• Dyspepsia: upset stomach or indigestion.
• Nasal congestion: blocked or runny nose.
• Back pain: discomfort in the lower back region.
• Visual disturbances: blurred vision or changes in colour perception.

Serious or Rare Side Effects

• Priapism: prolonged erection lasting more than four hours.
• Sudden vision loss: acute loss of vision in one or both eyes.
• Sudden hearing loss: unexplained loss of hearing or ringing in the ears.
• Cardiovascular events: chest pain, heart attack, or stroke in susceptible individuals.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Hypotension: marked drop in blood pressure causing dizziness or fainting.

Before prescribing Levitra, clinicians should evaluate patient history and comorbidities.

• Cardiovascular assessment: ensure the patient can tolerate sexual activity.
• Nitrate therapy: avoid concurrent use with nitrates due to risk of severe hypotension.
• Liver impairment: dose adjustment may be required in moderate to severe hepatic disease.
• Renal impairment: consider dose reduction in patients with severe renal dysfunction.
• Visual disorders: use caution in patients with retinal diseases such as retinitis pigmentosa.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Levitra can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Nitrates (e.g., nitroglycerin, isosorbide dinitrate): may cause life‑threatening hypotension.
• Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect leading to severe blood pressure drop.
• Strong CYP3A4 inhibitors (e.g., ritonavir): can markedly increase Vardenafil plasma levels.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase exposure, requiring dose adjustment.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.
• Alpha‑blockers (e.g., doxazosin, tamsulosin): may cause additive blood pressure lowering; monitor blood pressure.